The Characterization of Novel Tissue Microbiota Using an Optimized 16S Metagenomic Sequencing Pipeline. PLoS ONE 2015, 10(11): e0142334.
Physiogenex, a leading contract research organization providing validated nutritional animal models to evaluate compounds targeting metabolic diseases, and Vaiomer, a pioneer in microbiome science focusing on the development of novel biomarkers, therapeutic targets and drugs for cardiometabolic diseases,announced they have entered into commercial partnership. Read more...
We will be presenting our results on blood and tissue metagenomic analysis of patients with metabolic disease.Full program at www.somedverona2015.org
We will present an E-poster on "16S metagenomics from adipose tissue of patients with metabolic disease".Take a look at the full conference program at www.wcitt2d.org.